Overview
NICE is unable to make a recommendation on pomalidomide (Imnovid) with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma in adults because Celgene did not provide an evidence submission.
Last reviewed: 25 September 2019
Next review: We will review this decision if the company decides to make a submission.